In the largest epigenome-wide study of cardiovascular risk to date, three DNA methylation risk scores (MRS) derived from leukocyte samples in 44,674 Million Veteran Program participants each roughly doubled the hazard of incident atherosclerotic cardiovascular disease (ASCVD) per standard deviation (HR range: 1.97–2.08). Among 17,114 ASCVD-free participants followed for a median 7.4 years, 2,789 developed ASCVD. Crucially, MRS improved net reclassification by correctly downgrading 3.6–5.4% of true non-events away from high-risk categories, without sacrificing calibration — a clinically meaningful benefit even when raw discrimination gains (ΔCPE: 0.013–0.016) were modest.
Blood-based epigenetic biomarkers occupy an underexplored niche between static genetic risk scores and dynamic clinical measures. Unlike polygenic risk scores, methylation patterns capture gene-environment interactions accumulated over a lifetime — smoking history, metabolic stress, and aging — making them conceptually powerful for residual-risk stratification. The ability to reclassify non-events is particularly valuable: avoiding unnecessary statin intensification or aggressive interventions in low-true-risk individuals has real clinical and economic weight. However, important caveats apply. The cohort is 89.6% male and predominantly veterans, limiting generalizability to women and civilian populations. The study is observational, and methylation signatures may reflect disease-prone physiology rather than causal pathways. As a preprint not yet peer-reviewed, the MRS construction methodology and incremental gains warrant independent replication before clinical adoption. Still, the scale and rigor here mark this as a genuinely significant — if not paradigm-shifting — advance in epigenetic cardiovascular medicine.